LCS
CELZ icon

Levin Capital Strategies’s Creative Medical Technology CELZ Stock Holding History

Levin Capital Strategies’s Portfolio CELZ Stock Details CELZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,000
Closed -$22K – 337
2021
Q4 		$22K Buy
+1,000
New +$21K ﹤0.01% 330

Other funds holding CELZ

SCA
Sassicaia Capital Advisers Jericho, New York $227M AUM 402.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Levin Capital Strategies's CELZ Position: Q1 2022 in Review

Levin Capital Strategies sold out of Creative Medical Technology (CELZ) in Q1 2022, closing a stake of 1,000 shares — an estimated $22K sold.

Levin Capital Strategies first reported a position in CELZ in Q4 2021 and held it in 1 quarter. The position peaked at $22K in Q4 2021. 14 funds tracked by Wall St. Rank hold CELZ as of Q1 2022.

  • Levin Capital Strategies reported no remaining Creative Medical Technology position as of Q1 2022 after selling out during the quarter.
  • Levin Capital Strategies sold 1,000 Creative Medical Technology shares in Q1 2022, an estimated $22K.
  • Levin Capital Strategies first reported a position in Creative Medical Technology in Q4 2021 and held it in 1 quarter.
  • Levin Capital Strategies's Creative Medical Technology position peaked at $22K in Q4 2021.
  • 14 funds tracked by Wall St. Rank held Creative Medical Technology as of Q1 2022.

Based on Levin Capital Strategies's 13F filing for Q1 2022, filed 2 May 2022.